Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Update (11/2007)

Executive Summary

Brief summaries of recent clinical developments in the device industry, including a new electronic wound monitor, a tiny radio with medical potential, cutting-edge diabetes research, and advanced imaging for cancer detection and treatment.

You may also be interested in...



Cizzle Biotechnology Ltd.

Cizzle Biotechnology is focusing on the gene Ciz1 and its variant, found in small-cell lung cancer. The trigger for the start-up's formation was the finding that cells require Ciz1 to grow, and that variant forms could be used for selective targeting of cancer cells, especially small-cell lung cancer. The company's founders have shown that blocking the disrupted form of Ciz1, using a small interfering RNA (siRNA) targeted to the variant, prevented cell proliferation and growth in vitro. The specificity of the Ciz1 variant also gives it potential as a biomarker for early detection of lung cancer.

Handheld Ultrasound Developer Exo Raised $220M In Series C

As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date. 

AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid

Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

MT035123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel